Kaisa Health Group Holdings Limited (0876) AI Stock Analysis

• Market Cap: €95.80M
• Dividend Yield: N/A
• Average Volume (3M): 34.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: -0.28%
• EPS Growth: -713.33%
• Country: HK
• Employees: 861
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Instruments & Supplies
• EPS (TTM): >-0.01
• Shares Outstanding: 5,042,139,000
• 10 Day Avg. Volume: 7,869,600
• 30 Day Avg. Volume: 34,399,200
• PEG Ratio: -0.14
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

Kaisa Health Group Holdings Limited's stock faces significant challenges. The most pressing issues are its financial performance, characterized by ongoing net losses and poor cash flow generation. Technical analysis shows some positive momentum, but the valuation remains unattractive due to negative earnings. The absence of earnings call data and notable corporate events leaves these as minor considerations. Overall, the stock score reflects a company struggling to improve its financial health, with some technical positivity but overshadowed by financial and valuation concerns.

Kaisa Health Group Holdings Limited Business Overview & Revenue Model

Company Description

Kaisa Health Group Holdings Limited, an investment holding company, manufactures and trades in dental prosthetics in the People's Republic of China and internationally. The company offers dental prosthetics, including crowns and bridges, removable full and partial dentures, implants, and full-cast restorations, as well as provides public health and medical services. It is also involved in the investment holding of convertible bonds, as well as provision of medical technology and health care project development, medical consultation, and other medical services. The company was formerly known as Mega Medical Technology Limited and changed its name to Kaisa Health Group Holdings Limited in January 2018. Kaisa Health Group Holdings Limited was founded in 1971 and is headquartered in Central, Hong Kong.

How the Company Makes Money

Kaisa Health Group Holdings Limited generates revenue through multiple streams. The primary source of income is the sale of pharmaceuticals and medical devices, which the company manufactures and distributes to various healthcare providers and consumers. Additionally, the company offers healthcare management services, which contribute to its earnings by providing specialized health solutions and consultancy to clients. Strategic partnerships with medical institutions and research entities further enhance the company's market reach and revenue potential. These collaborations often lead to the development of new products and services, aligning with market demands and contributing to sustainable growth.

Kaisa Health Group Holdings Limited Financial Statement Overview

Summary

Kaisa Health Group Holdings Limited faces significant financial challenges, including persistent net losses and negative operating cash flows. While the balance sheet reflects a strong cash position and low leverage, declining equity and asset values are concerning. The company needs to improve profitability and cash flow generation to enhance its financial health and sustain long-term operations.

Income Statement

The company has struggled with profitability, showing consistent net losses in recent years, including a significant net loss of $46.36 million in 2024. Revenue growth is stagnant, with a slight decline from 2023 to 2024. Gross profit margins are relatively stable but have not translated into operating profits, as evidenced by negative EBIT and EBITDA margins in 2024. Overall, the income statement reflects challenges in revenue growth and profitability.

Balance Sheet

The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.02 in 2024. Stockholders' equity has decreased over the years, impacting the equity ratio, which remains decent at 83.31% in 2024. The company maintains a strong cash position, with cash and short-term investments exceeding total debt. However, the decline in total assets and stockholders' equity over recent years raises concerns about long-term financial stability.

Cash Flow

The cash flow statement indicates challenges in generating positive cash flows. Operating cash flow was zero in 2024, and the company has recorded negative free cash flow in prior years. The inability to generate positive cash flow from operations is a critical weakness. The lack of capital expenditures in the latest year suggests potential underinvestment in growth opportunities.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	185.36M	185.88M	191.50M	209.63M	183.81M
Gross Profit	81.86M	81.07M	82.56M	97.42M	89.96M
EBITDA	-12.70M	27.56M	-132.02M	45.58M	-20.71M
Net Income	-46.35M	7.47M	-123.32M	2.36M	-39.69M
Balance Sheet
Total Assets	517.59M	605.07M	767.60M	971.33M	757.54M
Cash, Cash Equivalents and Short-Term Investments	149.61M	174.08M	173.45M	259.26M	176.60M
Total Debt	10.65M	18.00M	31.87M	32.28M	23.24M
Total Liabilities	91.10M	113.30M	296.69M	288.49M	110.04M
Stockholders Equity	431.15M	492.01M	485.33M	651.12M	636.52M
Cash Flow
Free Cash Flow	0.00	-45.51M	-81.53M	-137.09M	-59.42M
Operating Cash Flow	-32.32M	-34.64M	-67.53M	-122.00M	-29.18M
Investing Cash Flow	0.00	44.50M	2.02M	141.67M	-21.66M
Financing Cash Flow	0.00	-7.34M	-7.08M	70.09M	-6.59M

Kaisa Health Group Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0876, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.50 is Neutral, neither overbought nor oversold. The STOCH value of 26.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0876.

Kaisa Health Group Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%
0876	45 Neutral	€95.80M	―		―	-0.28%	-713.33%
SHWGF		$3.56B	12.47	8.95%	4.36%	―	―
50J		€1.03B	13.46	18.36%	23.34%	―	―
PWE		€217.30M	10.16	3.72%	120.35%	―	―
2276	68 Neutral	HK$17.83B	33.35	28.81%	0.95%	14.99%	31.70%
1501	67 Neutral	HK$4.40B	19.76	11.24%	1.20%	11.23%	20.39%

Kaisa Health Group Holdings Limited Corporate Events

Kaisa Health Group Expands Partnership Interests with Major Acquisition

Kaisa Health Group Holdings Limited announced a major transaction involving the acquisition of additional limited partnership interests in a limited partnership, valued at RMB80,000,000. This acquisition, classified as a major transaction and an exempted connected transaction under Hong Kong’s Listing Rules, requires shareholder approval and is subject to certain conditions. The transaction reflects Kaisa Health’s strategic efforts to enhance its investment portfolio and strengthen its market position, though it remains contingent on meeting specific conditions outlined in the Transfer Agreement.

Kaisa Health Group Holdings Limited Announces Annual General Meeting

Kaisa Health Group Holdings Limited has announced its upcoming annual general meeting scheduled for June 13, 2025, in Hong Kong. The meeting will cover several key business items, including the consideration of financial statements, re-election of directors, and authorization of director and auditor remuneration. Additionally, the company seeks approval to allot and issue additional shares, which could impact its capital structure and shareholder value.

Kaisa Health Group Issues Profit Warning for FY2024

Kaisa Health Group Holdings Limited has issued a profit warning for the fiscal year ending December 31, 2024. The company anticipates a net loss between HK$50 million and HK$60 million, a significant downturn from the net profit of approximately HK$6 million recorded in 2023. This change is primarily attributed to a one-off gain from the disposal of subsidiaries in 2023. The financial results are based on unaudited management accounts and are yet to be finalized, with a detailed announcement to follow.

Kaisa Health Group to Review Annual Results and Dividend Proposal

Kaisa Health Group Holdings Limited has announced that its board of directors will meet on March 24, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend, which could impact the company’s financial strategy and shareholder returns.